XBI241220P96500
- 2.00
- -1.60-44.44%
SPDR S&P Biotech ETF Newsroom
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
Live On CNBC, Joe Terranova Announces Sold SPDR Series Trust SPDR S&P Biotech ETF
PepGen Stock Craters 35% on FDA Clinical Hold
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target
Vertex Pharmaceuticals Analyst Ratings
Neurocrine Biosciences Analyst Ratings
The Nasdaq 100 is about to adjust, and these 11 companies may see a 50% increase in upside potential.
As the annual adjustment of the NASDAQ 100 Index approaches, a group of potential stocks is preparing to make their debut. This adjustment not only brings prestige to these companies but may also trigger a large-scale inflow of capital, further driving up stock prices.
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
SA Asks: How Should Investors Position Portfolios Ahead of Fed Vote?
SPDR S&P Biotech ETF Options Spot-On: On December 13th, 132.6K Contracts Were Traded, With 958.89K Open Interest
On December 13th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 132.6K options for the day, of which put options accounted for 67.25% of the total
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Exact Sciences Analyst Ratings
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Natera Analyst Ratings
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...